Total raised
—
Last: Undisclosed 2019-03
Stage
Seed
Founded
2014
Headcount
6
HQ
Jerusalem
Sector
Health Tech & Life Sciences
About
NEOPROL is the developer of a new formulation for anesthesia drugs. The companys NP-09 is an advanced preclinical development of an improved formulation and novel bioequivalent of propofol, with proven superiority over Diprivan. NEOPROLs formulation is based on an invention by Professor Nissim Garti.
Funding history · 1 round · — total
2019-03
Undisclosed
Undisclosed
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is NEOPROL's primary focus?
- NEOPROL is a developer of new formulations for anesthesia drugs, specifically focusing on intravenous induction and maintenance of anesthesia.
- What is NEOPROL's key product?
- NEOPROL's key product is NP-09, an advanced preclinical development of an improved formulation and novel bioequivalent of propofol, which has shown superiority over Diprivan.
- When was NEOPROL founded?
- NEOPROL was founded in August 2014.
- Who invented the formulation NEOPROL uses?
- NEOPROL's formulation is based on an invention by Professor Nissim Garti.
- What is NEOPROL's current development stage?
- NEOPROL is currently in the Seed stage of funding and its product is in the R&D stage.
- When did NEOPROL receive its last known funding round?
- NEOPROL received an undisclosed funding round in March 2019.
- Which investor participated in NEOPROL's March 2019 funding round?
- Integra Holdings was an investor in NEOPROL's undisclosed funding round in March 2019.
- How many employees does NEOPROL have?
- NEOPROL has 6 employees.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Materials & SubstancesNanomaterials
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareProviders
Business model
B2B
Tags
nanotechnologypharmaceuticalslife-sciences